3. Program Goals

4. Case 1: Woman With MDS

5. Risk: Cytogenetic Subgroups

6. IPSS Risk Classification System

7. Diagnostic Problems in MDS

8. New Cytogenetic Classification of MDS

9. Patient Assessment

10. Case 1: Woman With MDS (cont)

11. Benefit of ESAs

12. Lenalidomide for del 5q

13. Phase 2: Lenalidomide in Low-Risk MDS With Karyotypes Other Than del(5q)

14. Neutropenia and Response With Lenalidomide for del(5q)

15. Pros and Cons of Lenalidomide

16. Case 1: Woman With MDS (cont)

17. Time to First Response With Azacitidine

18. Lower-Risk Prognostic Scoring System

19. Possible Treatment Paradigm Based on Risk

20. Impact of IPSS Risk Category on Transplant Outcome

21. Characteristics Affecting Decision to Proceed to AlloSCT

22. Response With Azacitidine in Low-Risk MDS

23. OS After Azacitidine Failure in Low- or Intermediate-1 Risk MDS

24. Case 2

25. Hyposegmented Neutrophils

26. Case 2 (cont)

27. MDS/MPN Overlap Disorders

28. MDS With Bone Marrow Fibrosis

29. ET With Ringed Sideroblasts

30. OS Curves of ET, RARS, and RARS-T

31. Therapeutic Options

32. Azacitidine: Treatment of CMML

33. Lenalidomide + Prednisone for MF (ECOG)

34. Phase 2: Pomalidomide in MF

35. Duration of TI in Responders With Lenalidomide

36. Prediction of Lenalidomide Response Using the Response Signature

37. Case 3

38. Case 3 (cont)

39. Case 3 (cont)

40. Histology of ET, PMF, and ET or MF

41. WHO Criteria for PMF

42. WHO Criteria for PMF (cont)

43. IWG-MRT Prognostic Model

44. DIPSS Risk Assessment

45. Kaplan-Meier Estimate of Survival in PMF According to the DIPSS

46. Criteria for Post-PV MF

47. Effect of Ruxolitinib on Spleen Size

48. Side Effects of Ruxolitinib

49. Case 3 (cont)

50. Case 3 (cont)

51. Therapeutic Options

52. Benefit From Ruxolitinib

53. Reduction in Spleen Size Across Subgroups

54. Splenomegaly in MF Patient Pre- and Post-Therapy

55. Mutant Protein Target Specificity and Anticytokine Activity of JAK Inhibitors

56. COMFORT Study: OS of Patients Enrolled at MDACC With Ruxolitinib